Tavapadon, sold under the brand name Juvmo, is a dopamine receptor agonist used for the treatment of Parkinson's disease.https://www.rxabbvie.com/pdf/juvmo_pi.pdf It is taken by mouth.
Tavapadon was approved for medical use in the United States in September 2026.
Medical uses Tavapadon is indicated for the treatment of Parkinson's disease in adults.
Contraindications Tavapadon has no contraindications.
Side effects Side effects of tavapadon may include nausea, headache, dizziness, fatigue or asthenia, dysgeusia, vomiting, dry mouth, and anxiety. Other potential but less common side effects include hypotension, orthostatic hypotension, impulsive control problems, compulsive behaviors, hallucinations, psychotic-like behaviors, and dyskinesia.
Interactions Tavapadon is substrate for CYP3A4 and hence interacts with CYP3A4 inhibitors and inducers. In addition to being a CYP3A4 substrate, tavapadon is a CYP3A4 inducer and can interact with CYP3A4 substrates. It is also a CYP2C8 inhibitor and can interact with CYP2C8 substrates. Tavapadon is a BCRP inhibitor and can interact with substrates of this protein as well.
Pharmacology Pharmacodynamics Tavapadon acts as a highly selective partial agonist of the dopamine D1 receptor (Ki = 9nM; = 65%) and the dopamine D5 receptor (Ki = 13nM; = 81%). It has no significant affinity or functional activity at the D2-like receptors (D2, D3, D4) (Ki ≥ 4,870 to 6,720nM). Tavapadon also shows biased agonism for Gs-coupled signaling at the D1-like receptors.
Pharmacokinetics Peak levels of tavapadon are reached after approximately 2 to 4hours with oral administration. It shows dose-proportional pharmacokinetics across its maintenance dosage range. Food does not significantly modify the pharmacokinetics of tavapadon and it can be taken without regard for food. The volume of distribution of tavapadon is 63.5L. Its plasma protein binding is 93%, primarily to albumin. Tavapadon is primarily metabolized by CYP3A4. It has a major inactive metabolite. Unchanged tavapadon is excreted less than 1% in urine and feces. Its major inactive metabolite was excreted less than 5% in urine and feces. The elimination half-life of tavapadon is 25.5hours.
History Tavapadon was developed by Cerevel Therapeutics, which acquired it from Pfizer in 2018.
Society and culture Legal status Tavapadon was approved for medical use in the United States in September 2026.
Names Tavapadon is the international nonproprietary name, and the United States Adopted Name.https://searchusan.ama-assn.org/usan/documentDownload?uri=/unstructured/binary/usan/tavapadon.pdf
Tavapadon is sold under the brand name Juvmo.
References
External links